SCHEMBL1438538

SCHEMBL1438538

O=C(Cc1cccc(Cl)c1F)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ TRPA1 O75762 2/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ SMO Q99835 1/20 0.43
▸ MRGPRX4 Q96LA9 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ CES1 P23141 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28385822 0.84 MEN1 (0.54) MAPTL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL571251 0.84 CTBP2 (0.56) MAPTL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL867945 0.82 AKR1B1 (0.57) TRPA1TDP1AKR1B10UGT1A9ABCB11
SCHEMBL9894009 0.81 MDM2 (0.39) MAPTL3MBTL1MEN1KMT2AMRGPRX4
SCHEMBL9061930 0.81 SHBG (0.47) MAPTL3MBTL1MEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL1373839 0.81 AKR1B1 (0.55) TRPA1TDP1AKR1B10UGT1A9ABCB11
SCHEMBL8956355 0.78 ALDH1A1 (0.54) MAPTL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL7196858 0.78 MAPT (0.61) MAPTL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL30287815 0.77 P2RX7 (0.45) L3MBTL1TRPA1SMN1; SMN2NPC1RAB9A
SCHEMBL14691047 0.77 P2RX7 (0.45) L3MBTL1TRPA1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 — — EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 — — US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MAPT 582/4885L3MBTL1 676/4885MEN1 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback